 |
71 Diseases |  |
100 Trials |
|
100 Trials |  |
2706 News |  |
| «12...910111213141516171819...3738» |
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Votrient (pazopanib) / Novartis, Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? (Pubmed Central) - Nov 17, 2021
In the low platelet-to-lymphocyte ratio (PLR) subgroup, the OS of the patients administered eribulin for the first choice was longer than that of the others (HR = 0.32, 95%CI = 0.10-0.98, p = 0.046). Therefore, NLR and PLR might be used as prognostic indicators to dictate whether STS patients receive pazopanib, trabectedin, or eribulin.
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. (Pubmed Central) - Nov 17, 2021
In breast cancer patients with eribulin chemotherapy, good systemic immune status, such as ALC ≥ 1500/μl, was associated with less progression, particularly metastasis, and better prognosis. Furthermore, the biomarker "high-ALC (ALC ≥ 1500/μl) and PPL" was particularly useful as a prognostic marker following eribulin chemotherapy.
- Halaven (eribulin mesylate) / Eisai
Tumor Treating Fields in combination with the TERT-inhibitor eribulin have synergistic antiproliferative effects on human glioblastoma cells (Exhibit Hall D) - Nov 16, 2021 - Abstract #SNO2021SNO_476;
Additionally, a synergistic effect of the combined treatment of TTFields and eribulin synergistic was observed. Eribulin in combination with TTFields could be a new effective therapy for GBM.
- Halaven (eribulin mesylate) / Eisai
Real world data on outcome for HER2-positive metastatic breast cancer from two UK centres ([VIRTUAL]) - Nov 16, 2021 - Abstract #NCRI2021NCRI_160;
Dual anti-HER2 monoclonal antibodies (Trastuzumab and Pertuzumab) with taxane is the standard of care as first-line treatment and antibody-drug conjugate Trastuzumab Emtansine (TDM-1) as second-line therapy for HER2-positive metastatic breast cancer (MBC)...19/22 patients received 3rd-line treatment using a combination of chemotherapy ±Trastuzumab; Capecitabine (10 patients), Eribulin (4 patients)...Impact statement Our results highlight poor patient outcomes following progression on dual anti-HER2 treatment. It provides baseline real time data which can be used to compare efficacy of new therapeutic agents like Trastuzumab Deruxtecan approved in this setting.
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Nov 15, 2021
P2, N=32, Completed, Sponsor: University of Southern California
It provides baseline real time data which can be used to compare efficacy of new therapeutic agents like Trastuzumab Deruxtecan approved in this setting. Active, not recruiting --> Completed | Trial primary completion date: Aug 2020 --> Feb 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Clinical: Perfect rationale for a randomized study against an active control: Eribulin vs Eribulin plus Pembrolizumab for #liposarcoma #PlaceboNo #PlaceboLockdown #ctos2021 #sarcoma (Twitter) - Nov 12, 2021
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Clinical: Paper 32 - PHASE II STUDY OF ERIBULIN AND PEMBROLIZUMAB IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA: ➡️PFS rate of 67% at 12 weeks. Median PFS= 6.75 months. Rapid Progressors identified. By Suzanne George https://t.co/3HWB799WoA #CTOS2021 (Twitter) - Nov 12, 2021
- | Halaven (eribulin mesylate) / Eisai
Journal, IO biomarker: Eribulin activates the cGAS-STING pathway via the cytoplasmic accumulation of mtDNA. (Pubmed Central) - Nov 12, 2021
While all clinically approved MTAs share an antimitotic mechanism of action, their distinct effects on interphase microtubules can promote differential downstream signaling consequences. We show that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel, activates the cGAS-STING innate immune signaling pathway through the accumulation of mitochondrial DNA in the cytoplasm.
- |||||| Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov) - Nov 10, 2021
P3, N=300, Recruiting, Sponsor: Spanish Breast Cancer Research Group
We show that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel, activates the cGAS-STING innate immune signaling pathway through the accumulation of mitochondrial DNA in the cytoplasm. Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. (Pubmed Central) - Nov 5, 2021
The outcomes described for our cohort are consistent with those reported in the pivotal Study301 and subsequent observational studies. Further data from adequately-sized, ad hoc trials on eribulin use in second line for mTNBC are warranted to confirm our findings.
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer. (Pubmed Central) - Nov 4, 2021
This network meta-analysis suggests that ERI may provide an overall survival benefit in the overall locally advanced breast cancer/metastatic breast cancer populations and triple negative breast cancer subgroup compared to standard treatments. These findings support the use of ERI in second- or later-line treatment of patients with locally advanced breast cancer/metastatic breast cancer.
- || Halaven (eribulin mesylate) / Eisai
Clinical, P2 data, Clinical Trial,Phase II, Journal: A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). (Pubmed Central) - Nov 4, 2021
Sequential administration of eribulin after the A/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.
- |||||||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
New P3 trial, Metastases: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov) - Nov 2, 2021
P3, N=700, Recruiting, Sponsor: AstraZeneca
- Halaven (eribulin mesylate) / Eisai
[VIRTUAL] “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy,” () - Nov 1, 2021 - Abstract #SWOGFall2021SWOG_Fall_78;
- || Halaven (eribulin mesylate) / Eisai
Biomarker, Clinical, P2 data, Journal, Combination therapy, BRCA Biomarker: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). (Pubmed Central) - Oct 31, 2021
P2
The combination of eribulin and gemcitabine showed promising activity and a moderate toxicity profile in metastatic TNBC. BRCA status and pharmacogenetics tests may help identify patients with high probability of response with negligible toxicity.
- || Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Clinical, P2 data, Journal, Combination therapy: Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). (Pubmed Central) - Oct 31, 2021
BRCA status and pharmacogenetics tests may help identify patients with high probability of response with negligible toxicity. The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC.
- || Halaven (eribulin mesylate) / Eisai, Perjeta (pertuzumab) / Roche
Clinical, Journal: Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. (Pubmed Central) - Oct 31, 2021
P=N/A
OS has dramatically improved among HER2+ MBC patients, probably in association with the release of several major HER2-directed therapies, whose penetrance was high. This trend was not observed in the other subtypes, but the impact of CDK4/6 inhibitors cannot yet be assessed.
- || Halaven (eribulin mesylate) / Eisai
Biomarker, Clinical, P2 data, Journal: Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11). (Pubmed Central) - Oct 31, 2021
Genetic polymorphisms of rs1044457 in CMPK1, rs693955 in SLC29A1, and rs2807312 in TLE4 were significantly associated with the 6-month PFS rate and/or the duration of PFS. Further studies with a larger sample size and expression study would be helpful to validate the association of genetic polymorphisms and clinical efficacy of gemcitabine.
- Halaven (eribulin mesylate) / Eisai
[VIRTUAL] Combination Treatment of Irradiation and Tumor Treating Fields for Human Glioblastoma Cells (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_2249;
For the combined treatment of TTFields and eribulin synergistic effects on cell proliferation were observed. Our data highlight the therapeutic potential of eribulin used in combination with TTFields and offer important insights for possible new effective GBM therapies.
- | Halaven (eribulin mesylate) / Eisai
Journal: Combination Treatment of Irradiation and Tumor Treating Fields for Human Glioblastoma Cells. (Pubmed Central) - Oct 29, 2021
For the combined treatment of TTFields and eribulin synergistic effects on cell proliferation were observed. Our data highlight the therapeutic potential of eribulin used in combination with TTFields and offer important insights for possible new effective GBM therapies.
- | Halaven (eribulin mesylate) / Eisai
Preclinical, Journal: Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin. (Pubmed Central) - Oct 28, 2021
Our data highlight the therapeutic potential of eribulin used in combination with TTFields and offer important insights for possible new effective GBM therapies. CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. (Pubmed Central) - Oct 27, 2021
P2
Pembrolizumab plus eribulin demonstrates encouraging antitumour activity in patients with heavily pre-treated, HR+, HER2-negative, locally recurrent or metastatic BC. The safety and tolerability of the combination is similar to eribulin or pembrolizumab monotherapy.
- | Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial initiation date, Trial primary completion date, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - Oct 26, 2021
P1/2, N=41, Not yet recruiting, Sponsor: Colette Shen
The safety and tolerability of the combination is similar to eribulin or pembrolizumab monotherapy. Trial completion date: Feb 2024 --> Feb 2026 | Initiation date: Aug 2021 --> Feb 2022 | Trial primary completion date: Feb 2022 --> Feb 2023
- balixafortide (POL 6326) / Polyphor, Halaven (eribulin mesylate) / Eisai
Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS) (Stars at Night 1/2) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1519;
Efficacy parameters for E alone were similar to those reported previously. The combination was B + E was well-tolerated overall.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Halaven (eribulin mesylate) / Eisai
Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1434;
P3
Pts who received post PD therapy following SG had significantly improved median OS over those who did not receive further therapy. Pts who received eribulin, carboplatin, atezolizumab, or capecitabine, as post PD therapy had similar median OS.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Halaven (eribulin mesylate) / Eisai
Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1427;
P3
While only 12% of pts in the ASCENT trial self-identified as Black, Black pts with pretreated mTNBC derived a similar clinical benefit from SG over TPC as seen in the full trial population, with a manageable safety profile. SG should be considered as a treatment option for pts with mTNBC in the 2L+ setting.
- Halaven (eribulin mesylate) / Eisai
Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple‑negative breast cancer (mTNBC) (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1421;
Although patients treated with SG reported higher rates of diarrhea, this did not generate a negative impact on their overall quality of life or functioning. T able : M ixed effects model least-square mean EORTC QLQ - C30 score changes from baseline
- Halaven (eribulin mesylate) / Eisai, eribulin/farletuzumab ADC (MORAb-202) / Eisai
MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1311;
The major toxicity observed with MORAb-202 treatment was hematologic toxicity. Conclusion These findings suggest MORAb-202 may be a promising ADC for TNBC and warrants further clinical investigation in this setting.
- Halaven (eribulin mesylate) / Eisai
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin as the first-line chemotherpy. Combined analysis of two phase 2 study (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1125;
In addition, those with NLR less than 3 had better PFS and OS than those with NLR 3 or more. In comparison with the capecitabine group, although low NLR was a good prognostic factor not only in eribulin group but also in capecitabine group, high ALC was suggested to be a particular prognostic factor of eribulin.
- Halaven (eribulin mesylate) / Eisai
Eribulin treatment for hormone receptor positive breast cancer cells with resistant to endocrine therapy promotes re-expression of estrogen receptor (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1086;
Eribulin improve the tumor microenvironment changed by hypoxia, and induce re-expression of ER in hypoxia resistant breast cancer cells. Eribulin treatment for HR positive breast cancer with resistance to endocrine therapy makes possibility of re-administration of endocrine therapy.
- Halaven (eribulin mesylate) / Eisai
Eribulin alters the chromatin landscape to induce MET, attenuating metastatic progression and sensitizing breast tumors to subsequent chemotherapy (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_881;
Additionally, the efficacy of eribulin is highest when administered in the treatment-naïve setting. By developing an understanding of eribulin’s mechanism of action, treatment strategies can be optimized to maximize therapeutic potential by exploiting its effects in both mitotic blockade as well as MET.
- AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine
Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_825;
P2
This trial is currently ongoing. ClinicalTrials.gov number, NCT04303741.
- Halaven (eribulin mesylate) / Eisai
A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_763;
P2
All pts underwent curative surgery despite low pCR rate, commonly observed in ER+ IBC. There were changes in some DCE-MRI parameters after exposure to chemotherapy but may not be specific to E. Studies specifically designed for IBC are needed to enhance the understanding of this disease.
- Halaven (eribulin mesylate) / Eisai
Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_544;
However, in multivariable analysis, response, defined as PFS > 4 months, was not statistically associated with response to the previous treatment line. Therefore, a lack of response to first, second-, - or third-line chemotherapy should not trigger discontinuation of anticancer therapy in case of further available treatment options.
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Journal: Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. (Pubmed Central) - Oct 22, 2021
P2
Broadly, we establish a framework for ICI response in HR+ breast cancer that warrants diagnostic and therapeutic validation. ClinicalTrials.gov Registration: NCT03051659.
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) (clinicaltrials.gov) - Oct 22, 2021
P2, N=23, Active, not recruiting, Sponsor: Eisai Inc.
ClinicalTrials.gov Registration: NCT03051659. Recruiting --> Active, not recruiting | N=45 --> 23 | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Jan 2021
- | Talzenna (talazoparib) / Pfizer
Journal, HEOR, Monotherapy: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. (Pubmed Central) - Oct 20, 2021
The economic evaluation conducted shows an elevated incremental cost-utility ratio and budgetary impact. Taking these results into account, the price of talazoparib would have to be lower than that taken as a reference to reach the cost-utility thresholds.
- |||| Margenza (margetuximab) / MacroGenics, ZAI Lab
Trial completion date, Trial primary completion date, Metastases: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Oct 19, 2021
P3, N=624, Active, not recruiting, Sponsor: MacroGenics
Taking these results into account, the price of talazoparib would have to be lower than that taken as a reference to reach the cost-utility thresholds. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Aug 2021
- || Halaven (eribulin mesylate) / Eisai, VS-6766 / Verastem
Clinical, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: The novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of TNBC. (Pubmed Central) - Oct 15, 2021
We also showed the suppressed expression of PD-L1 in the combination therapy in vivo. We demonstrated that combination therapy with eribulin and CH5126766 for triple-negative breast cancer inhibited cell growth by apoptosis and raised a possibility that immune responses through suppression of PD-L1 might partially contribute to inhibition of tumor growth, indicating the potential of this combination as a novel strategy for triple-negative breast cancer.
- || Halaven (eribulin mesylate) / Eisai
Biomarker, P2 data, Clinical Trial,Phase II, Journal: An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer. (Pubmed Central) - Oct 14, 2021
We demonstrated that combination therapy with eribulin and CH5126766 for triple-negative breast cancer inhibited cell growth by apoptosis and raised a possibility that immune responses through suppression of PD-L1 might partially contribute to inhibition of tumor growth, indicating the potential of this combination as a novel strategy for triple-negative breast cancer. In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.
- || ifosfamide / Generic mfg.
Clinical, Journal: Long-Term Survival of a Patient with Recurrent Dedifferentiated High-Grade Liposarcoma of the Retroperitoneum Under Adjuvant Treatment with Viscum album L. Extract: A Case Report. (Pubmed Central) - Oct 13, 2021
Three months after this first surgery, a recurrence occurred, and was treated with neoadjuvant and adjuvant doxorubicin plus ifosfamide and surgery (resection)...Finally, a fifth recurrence-5 months after the fifth surgery-was treated with subcutaneous and intravenous VAE applications and eribulin...On the basis of the antitumoral and immunomodulating effects of VAE and on the reported prolonged survival of VAE-treated patients with other types of tumors, the adjunct VAE treatment is presumed to have contributed to the favorable outcome. Regarding the clinical relevance of VAE treatment, further investigations are needed.
- Halaven (eribulin mesylate) / Eisai, Margenza (margetuximab) / MacroGenics, ZAI Lab
Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis (Stars at Night 3/4) - Oct 9, 2021 - Abstract #SABCS2021SABCS_258;
P3
An exploratory analysis of CD16A genotyping indicates a numerical OS advantage in favor of M in F homozygous pts, along with a numerical OS advantage in favor of T in V homozygous pts. Safety of M + CTX was similar to previous reports and consistent with M FDA-approved label.
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal, HEOR: Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan. (Pubmed Central) - Oct 8, 2021
Although eribulin showed an attenuated effect in the real-world setting in Taiwan, it may serve as an alternative for capecitabine in a heavy pretreated population. The total healthcare and medication costs were found to be higher with eribulin treatment.
- Halaven (eribulin mesylate) / Eisai
Overcoming eribulin resistance in human breast cancer cells by ibrutinib () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1163;
Ibrutinib can partly reverse eribulin resistance when applied in high doses. The suppression of the ERK1 / 2 activity by ibrutinib may be one of its mechanisms.
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Implementation of new tests and treatments for patients with advanced triple negative breast cancer in routine care - data from the registry platform OPAL () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1160;
P=N/A
BRCA1 / 2 testing is performed less often, especially in first-line situation. With longer follow-up, OPAL will show the impact of these new targeted therapies on the outcome in routine care.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Halaven (eribulin mesylate) / Eisai
Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1153;
P3
Irrespective of age, pts who received SG had a significant survival benefit vs TPC, with a tolerable safety profile. Proactive AE monitoring and management will allow optimal therapeutic exposure to SG in older pts.
- |||| Halaven (eribulin mesylate) / Eisai
FDA event, NCCN guideline, Reimbursement, Review: An insurance company requesting a peer-to-peer review for eribulin usage in metastatic breast cancer? @US_FDA approved and @NCCN guideline level 1 evidence. It is the most unproductive 30 min. Similar things happen too often. #bcsm (Twitter) - Oct 6, 2021
- ||||| Halaven (eribulin mesylate) / Eisai
Clinical: Dr. Wozniak unraveling mechanism of action of eribulin in patients with #leiomyosarcoma @NationalLMSF research roundtable (Twitter) - Oct 1, 2021
- Halaven (eribulin mesylate) / Eisai
[VIRTUAL] GDF15 contributes to the maintenance of the drug-tolerant persister state in cells responding to eribulin () - Sep 30, 2021 - Abstract #AACRNCIEORTC2021AACR_NCI_EORTC_229;
- |||||||||| Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
New P3 trial, Metastases: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov) - Sep 30, 2021
P3, N=300, Not yet recruiting, Sponsor: Spanish Breast Cancer Research Group